- Home
- HOFT vs AGEN Comparison
HOFT vs AGEN Comparison
Compare HOFT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOFT | AGEN |
|---|---|---|
| Founded | 1924 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 126.2M |
| IPO Year | 1999 | 1999 |
Fundamental Metrics
Financial Performance| Metric | HOFT | AGEN |
|---|---|---|
| Price | $13.64 | $3.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 35.3K | ★ 365.1K |
| Earning Date | 03-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | ★ $397,465,000.00 | $42,877,086.00 |
| Revenue This Year | N/A | $5.19 |
| Revenue Next Year | $2.61 | $68.25 |
| P/E Ratio | ★ N/A | $8.64 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $7.34 | $1.38 |
| 52 Week High | $15.99 | $7.34 |
Technical Indicators
Market Signals| Indicator | HOFT | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.14 | 49.64 |
| Support Level | $13.69 | $2.90 |
| Resistance Level | $15.99 | $4.68 |
| Average True Range (ATR) | 0.70 | 0.18 |
| MACD | -0.19 | 0.04 |
| Stochastic Oscillator | 36.94 | 69.35 |
Price Performance
Historical ComparisonAbout HOFT Hooker Furnishings Corporation
Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).